

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. – 15. (Cancelled)

16. (Currently amended) A compound according to claim ~~4~~17 or 18, which can exist as optical isomers, wherein said compound is either the racemic mixture or the individual optical isomers.

17. (Currently amended) A compound ~~according to claim 1, wherein said compounds are selected from~~ the group consisting of:

~~(4-Fluoro-phenyl)-[3-(4-fluoro-phenylethynyl)-piperidin-1-yl]-methanone~~

~~(4-Fluoro-phenyl)-[3-[5-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl]-methanone~~

(S)-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone;

(S)-(thiophen-2-yl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-methyl-2-pyrazin-2-yl-thiazol-5-yl)-methanone;

(2,4-Difluoro-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(3,4,5-trifluoro-phenyl)-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(5-pyridin-2-yl-thiophen-2-yl)-methanone;

Cyclopentyl-[(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl]-methanone;

(3,4-Difluoro-phenyl)-[(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl]-methanone;

Benzothiazol-6-yl-[(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl]-methanone;

(3,5-Dimethyl-isoxazol-4-yl)-[(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl]-methanone;

(4-Fluoro-phenyl)-[(S)-3-[3-(2,4,6-trifluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl]-methanone;

~~(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone~~

~~(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone~~

{(S)-3-[3-(2,4-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-fluoro-phenyl)-methanone;

(4-Fluoro-phenyl)-[(S)-3-(3-p-tolyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone;

(4-Fluoro-phenyl)-[(S)-3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl]-methanone;

~~(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone~~

~~(4-Fluoro-phenyl)-[3-[5-(4-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-piperidin-1-yl]-methanone~~

(2-Fluoro-phenyl)-[(S)-3-[2-(3,4-difluoro-phenyl)-1,2,4]oxadiazol-5-yl]-piperidin-1-yl]-methanone;

~~(4-Fluoro-phenyl)-[2-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl]-methanone~~

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-thiophen-3-yl-methanone;

~~(4-Fluoro-phenyl)-[3-(5-phenyl-tetrazol-2-yl)-piperidin-1-yl]-methanone~~

(4-Fluoro-phenyl)-[(S)-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone;
and
 (3,4-Difluoro-phenyl)-[(S)-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-
 methanone;

18. (Currently amended) A compound ~~according to claim 1, wherein said~~
~~compounds are selected from the group consisting of:~~

{3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone;
 {3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone;
 (4-Fluoro-phenyl)-[3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone;
 (3-Fluoro-phenyl)-[3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone;
 (4-Fluoro-phenyl)-{3-[3-(3-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-
 methanone;

(3-Fluoro-phenyl)-{3-[3-(3-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-
 methanone;

(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-
 methanone;

(3-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-
 methanone;

(*R*)-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-
 methanone;

~~(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-~~
~~methanone~~

~~(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-~~
~~yl}-methanone~~

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-phenyl-thiazol-4-yl)-
 methanone;

{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-methyl-6-
 trifluoromethyl-pyridin-3-yl)-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-[1,2,3]thiadiazol-4-yl-methanone;

Benzothiazol-2-yl-{{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone};

{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(5-methyl-isoxazol-3-yl)-methanone;

(1,5-Dimethyl-1H-pyrazol-3-yl)-{{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone};

{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone;

4-{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine-1-carbonyl}-benzonitrile};

{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-isoxazol-5-yl-methanone;

(3-Chloro-4-fluoro-phenyl)-{{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone};

{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-phenyl-2H-pyrazol-3-yl)-methanone;

{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(5-methyl-2-phenyl-2H-[1,2,3]triazol-4-yl)-methanone;

(4-Fluoro-3-methyl-phenyl)-{{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone};

{{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(3-methyl-thiophen-2-yl)-methanone;

{{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(1-methyl-1H-pyrrol-2-yl)-methanone;

{{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-thiazol-2-yl-methanone;

{{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(4-methyl-thiazol-5-yl)-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(6-morpholin-4-yl-pyridin-3-yl)-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(1H-indol-5-yl)-methanone;

2-(4-Fluoro-phenyl)-1-{{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-ethanone};

3-(4-Fluoro-phenyl)-1-{{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-propan-1-one};

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-isoquinolin-3-yl-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-quinoxalin-6-yl-methanone;

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-benzoimidazol-6-yl-methanone;

~~(4-Fluoro-phenyl)-{(S)-3-[3-(3-naphthalen-1-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone}~~

{(S)-3-[3-(2,6-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-fluoro-phenyl)-methanone;

(4-Fluoro-phenyl)-{(S)-3-[3-(2-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone;

~~(4-Fluoro-phenyl)-{(S)-3-[3-(3-naphthalen-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone}~~

~~(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone}~~

~~(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-methanone}~~

~~(S)-1-(4-Fluoro-benzoyl)-piperidine-3-carboxylic acid (4-fluoro-phenyl)-amide;~~

~~(S)-1-(4-Fluoro-benzoyl)-piperidine-3-carboxylic acid (4-fluoro-phenyl)-methyl-amide;~~

(E)-3-(4-Fluoro-phenyl)-1-{{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-propenone};

~~1-(4-((S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine-1-carbonyl)-piperidin-1-yl)-ethanone~~
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-imidazol-1-yl-phenyl)-methanone;
(4-Fluoro-phenyl)-{(S)-3-[3-(4-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone; and
(3,4-Difluoro-phenyl)-{(S)-3-[3-(4-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone.

19. (Cancelled)

20. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim ~~4~~17 or 18 and pharmaceutically acceptable carriers and/or excipients.

21. (Withdrawn-Currently amended) A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR5 allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claim 17 or 18~~4~~.

22. (Withdrawn-Currently amended) A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR5 positive allosteric modulators (enhancer), comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound according to claim 17 or 18~~4~~.

23. (Withdrawn-Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of anxiety disorders: Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-

Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, comprising administering an effective amount of a compound according to claim 17 or 18.

24. (Withdrawn-Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of childhood disorders: Attention-Deficit/Hyperactivity Disorder), comprising administering an effective amount of a compound according to claim 17 or 18.

25. (Withdrawn-Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of eating Disorders (Anorexia Nervosa, Bulimia Nervosa), comprising administering an effective amount of a compound according to claim 17 or 18.

26. (Withdrawn-Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of mood disorders: Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, Substance-Induced Mood Disorder, comprising administering an effective amount of a compound according to claim 17 or 18.

27. (Withdrawn – Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of psychotic disorders: Schizophrenia, Delusional Disorder, Schizoaffective Disorder, Schizophreniform Disorder, Substance-Induced Psychotic Disorder, comprising administering an effective amount of a compound according to claim 17 or 18.

28. (Withdrawn-Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of cognitive disorders: Delirium, Substance-Induced Persisting Delirium, Dementia, Dementia Due to HIV Disease, Dementia Due to Huntington's Disease, Dementia Due

to Parkinson's Disease, Dementia of the Alzheimer's Type, Substance-Induced Persisting Dementia, Mild Cognitive Impairment, comprising administering an effective amount of a compound according to claim 17 or 18.

29. (Withdrawn-Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of personality disorders: Obsessive-Compulsive Personality Disorder, Schizoid, Schizotypal disorder, comprising administering an effective amount of a compound according to claim 17 or 18.

30. (Withdrawn-Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of substance-related disorders: Alcohol abuse, Alcohol dependence, Alcohol withdrawal, Alcohol withdrawal delirium, Alcohol-induced psychotic disorder, Amphetamine dependence, Amphetamine withdrawal, Cocaine dependence, Cocaine withdrawal, Nicotine dependence, Nicotine withdrawal, Opioid dependence, Opioid withdrawal, comprising administering an effective amount of a compound according to claim 17 or 18.

31. - 32. (Cancelled)

33. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, the method comprising administering a compound of claim 17 or 18 to the mammal.

34. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to Attention-Deficit/Hyperactivity Disorder, or an Eating disorder, the method comprising administering a compound of claim 17 or 18 to the mammal.

35. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to an Eating disorder, the method comprising administering a compound of claim 17 or 18~~1~~ to the mammal.

36. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, or Substance-Induced Mood Disorder, the method comprising administering a compound of claim 17 or 18~~1~~ to the mammal.

37. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to Schizophrenia, Delusional Disorder, Schizoaffective Disorder, Schizophreniform Disorder, or Substance-Induced Psychotic Disorder, the method comprising administering a compound of claim 17 or 18~~1~~ to the mammal.

38. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to Delirium, Substance-Induced Persisting Delirium, Dementia, Dementia Due to HIV Disease, Dementia Due to Huntington's Disease, Dementia Due to Parkinson's Disease, Dementia of the Alzheimer's Type, Substance-Induced Persisting Dementia, or Mild Cognitive Impairment, the method comprising administering a compound of claim 17 or 18~~1~~ to the mammal.

39. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to Obsessive-Compulsive Personality Disorder, Schizoid, or Schizotypal disorder, the method comprising administering a compound of claim 17 or 18~~1~~ to the mammal.

40. (Withdrawn-Currently amended) A method for treating a mammal suffering from or susceptible to Alcohol abuse, Alcohol dependence, Alcohol withdrawal, Alcohol withdrawal delirium, Alcohol-induced psychotic disorder,

Amphetamine dependence, Amphetamine withdrawal, Cocaine dependence, Cocaine withdrawal, Nicotine dependence, Nicotine withdrawal, Opioid dependence, or Opioid withdrawal, the method comprising administering a compound of claim ~~4~~17 or 18 to the mammal.

41. (Currently amended) A pharmaceutical composition comprising a compound of claim ~~4~~17 or 18.

42. (Previously presented) A pharmaceutical composition of claim 41 further comprising a pharmaceutically acceptable carrier.

43. (Withdrawn-Currently amended) A method to prepare a tracer to for imaging metabotropic glutamate receptors, comprising using a compound of claim 17 or 18.